TOP TEN perturbations for 1543_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1543_at
Selected probe(set): 205698_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1543_at (205698_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.720543
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

stem cell differentiation study 47 (BMP-2; IBMX; 2d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):3.6017818
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

azathioprine study 7 (250uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):-3.3944578
Number of Samples:3 / 21
Experimental azathioprine study 7 (250uM)
HepG2 cells treated with compound: azathioprine (250uM; CAS no.:446-86-6) for 24 hours. Azathioprine is hepatotoxic and may cause cholestasis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):3.34799
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

stem cell differentiation study 47 (BMP-2; IBMX; 3d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):3.33601
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 3d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 3 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 3 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):3.2137518
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

SW620 / SW480

Relative Expression (log2-ratio):3.212244
Number of Samples:62 / 63
Experimental SW620
Human metastatic cancer cell line derived from the lymph node of a patient with adenocarcinoma of the colon. Synonyms:SW-620; SW 620; SW.620 Cellosaurus code:
Control SW480
Human primary cancer cell line derived from the colon of a male patient with adenocarcinoma. Synonyms:SW-480; SW 480; SW480E Cellosaurus code:

RAF1 depletion study 1 / control vector transfected SW-480 cell sample

Relative Expression (log2-ratio):3.1980715
Number of Samples:6 / 6
Experimental RAF1 depletion study 1
RNAi-mediated gene knockdown of RAF1 in colorectal cancer cell line SW-480.
Control control vector transfected SW-480 cell sample
SW-480 colorectal cell line sample transduced with empty vector pLKO.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (endometrioid carcinoma; metastatic)

Relative Expression (log2-ratio):-3.1589336
Number of Samples:2 / 3
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.1578274
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).